Phaseline

Companies › Bioverativ, a Sanofi company

Bioverativ, a Sanofi company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Hematology; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Efanesoctocog Alfa (BIVV001)
Coagulation factor VIII exogenous protein
F8Phase 3Hemophilia AJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04644575Efanesoctocog Alfa (BIVV001)Phase 3Hemophilia AHematologyJan 2027

From the company's SEC filings

Complete response letters from FDA

Targets

F8 (1)

Companies with the same targets

Pfizer Roche Swedish Orphan Biovitrum Sinocelltech Octapharma ASC Therapeutics Biocad Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical

Companies built like this

Hangzhou Gensciences Biopharmaceutical Gritgen Therapeutics Forma Therapeutics Wuhan Createrna Science and Technology Pharmanutra

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.